A nanowire-based liquid biopsy method using cerebrospinal fluid cell-free DNA for targeted management of leptomeningeal carcinomatosis

Choi, Wonyoung; Cho, Youngnam; Park, Seog-Yun; Hwang, Kum Hui; Han, Ji‐Youn; Lee, Youngjoo

doi:10.1007/s00432-020-03324-5

Cited by 10 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 21 , 24 The same phenomenon was also found in patients with C797S mutation in CSF who received first‐ or second‐generation TKI. 24 However, after third‐generation TKI treatment failure, the mutated rate of T790M in CSF became higher than in plasma, 23 which illustrated the third‐generation TKI has a certain degree of CNS permeability, but the response of LM is not as obvious as extracranial lesions. Due to the different CNS permeability of TKI, dynamic changes of T790M in plasma seem to be more sensitive than that in CSF, even though there was a definite progression of LM.…”

Section: Resultsmentioning

confidence: 60%

“…A total of 17 articles were included in this review according to the eligibility criteria through full‐text reading 8 , 9 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 (Figure 1 ). Eleven patients in two studies reported by Ma et al were duplicates but the study content was different.…”

Section: Resultsmentioning

confidence: 99%

“…The number of patients with matched EGFR mutations detected in CSF to the primary tumor were 9/11, 9/10, 3/5, 7/9, 21/29, 5/5, and 7/11, respectively. 13 , 15 , 17 , 19 , 20 , 24 , 26 …”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Sequencing of cerebrospinal fluid in non‐small‐cell lung cancer patients with leptomeningeal metastasis: A systematic review

Gao

Chen

2022

Cancer Medicine

View full text Add to dashboard Cite

Leptomeningeal metastasis (LM) refers to the dissemination of malignant cells in the subarachnoid space, pia, and arachnoid mater and is a severe condition associated with metastatic solid tumors. The most common solid tumor that develops into LM is lung cancer and the incidence increased in patients with advanced non‐small‐cell lung cancer (NSCLC) with targetable mutations. However, tissue biopsy of LM is inaccessible, leading to the paucity of genomic profiles of LM to guide targeted treatments and explore biological mechanisms. In recent years, liquid biopsy is considered a minimally invasive and dynamic method to trace the genomic alterations of cancer cells and some studies started to perform sequencing of cerebrospinal fluid (CSF) in patients with LM to reveal the targeted mutations and genomic profiles. In this review, we focused on studies performed sequencing of CSF in NSCLC patients with LM and summarized the sequencing results and their commonality. As the only way to reveal the genomic landscapes of LM, our review provided evidence that sequencing of CSF is a promising management method in LM patients to dynamically guide target therapy and monitor intracranial tumor response. Furthermore, it reveals a unique genomic profile of LM including driver genes, drug‐resistant mutations, and a number of copy number variations. Sequencing of CSF in LM patients seems to provide more comprehensive genomic information than we expected and the biological significance behind the genomic alternations needs further study.

show abstract

Section: Resultsmentioning

confidence: 60%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Sequencing of cerebrospinal fluid in non‐small‐cell lung cancer patients with leptomeningeal metastasis: A systematic review

Gao

Chen

2022

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…On the other hand, cell-free DNA extracted from CSF of patients with cancer is thought to be enriched for ctDNA due to the significantly lower number of normal cells in CSF compared with that in blood. Using [17,20,[36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53]). Most studies have focused on patients with EGFR-mutant NSCLC with LM due to the relatively high number of these patients [10].…”

Section: Cell-free Tumor Dnamentioning

confidence: 99%

“…mutation allele-specific amplification, Swinkels et al[36] first identified KRAS mutation in CSF of two patients with NSCLC with LM. Subsequent studies, using either polymerase chain reaction (PCR) or NGS, have demonstrated that CSF ctDNA is a feasible material for mutation detection, particularly in patients with LM, with a detection rate as high as 100%[17,[37][38][39][40][41][42][43][44][45][46][47][48][49][50]. Published studies on ctDNA in CSF of patients with NSCLC with CNS metastasis are summarized in Table2(Ref.…”

mentioning

confidence: 99%

Cerebrospinal fluid as a medium of liquid biopsy in the management of patients with non-small-cell lung cancer having central nervous system metastasis

Chiang¹,

Huang²,

Luo³

et al. 2021

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

The molecular profiling of tumors is fundamental in the management of advanced non-small-cell lung cancer (NSCLC). A tissue specimen obtained from biopsy is needed for diagnosis and mutation analysis. However, this may not be feasible for some metastatic sites, such as central nervous system (CNS) lesions, particularly for repeated biopsy. Liquid biopsy with plasma is an emerging tool for molecular testing and could be a surrogate method if tissue cannot be obtained. However, the use of plasma is limited for the detection of mutations arising from intracranial lesions. Cerebrospinal fluid (CSF) was recently demonstrated to be an alternative material for genetic testing in patients with NSCLC having CNS metastasis. In this review, we discuss recent advancement in the use of CSF as a medium of liquid biopsy in patients with NSCLC.This study was funded by Taipei Veterans General Hospital, Taiwan (V110B-008).

show abstract

Liquid biopsy in the setting of leptomeningeal metastases: a systematic review and meta-analysis

Wijaya,

Patel,

Quintero-Consuegra

et al. 2023

J Neurooncol

View full text Add to dashboard Cite

A nanowire-based liquid biopsy method using cerebrospinal fluid cell-free DNA for targeted management of leptomeningeal carcinomatosis

Cited by 10 publications

References 36 publications

Sequencing of cerebrospinal fluid in non‐small‐cell lung cancer patients with leptomeningeal metastasis: A systematic review

Sequencing of cerebrospinal fluid in non‐small‐cell lung cancer patients with leptomeningeal metastasis: A systematic review

Cerebrospinal fluid as a medium of liquid biopsy in the management of patients with non-small-cell lung cancer having central nervous system metastasis

Liquid biopsy in the setting of leptomeningeal metastases: a systematic review and meta-analysis

Contact Info

Product

Resources

About